News roundup Monday, November 25

The latest from BioStock

» Capital injection to bring Xspray to market
» Xspray wants to launch better cancer drugs – CEO explains how
» Another successful Summit – see all videos here
» Xspray's CEO on the 2025 launch plan
» Lipum presents promising Phase I data at ACR 2024

Read the newsletter for v.47 here.

Last week was held BioStock Life Science Summit 2024 at Medicon Village in Lund. Anyone who was not there can now see all the features hereThe list will be updated gradually.

The latest news

All primary and secondary endpoints achieved in phase I study with NEX-22. Read moreThe company invites you to a webcast. Read more.

BiBBInstruments announces that the company's clinical evaluation continues at Karolinska University Hospital. Read more.

Positive results in AstraZeneca phase III study CAPITello-281 in prostate cancer. Read more.

The third period of exploitation for Xintelas Series TO3 warrants begin today. Read more.

French hospital connects to regional pathology solution from sectra. Read more.

Article published by ASSET, coordinated by Diamyd Medical, advocates national screening programs in Sweden for early detection of type 1 diabetes. Read more.

Bioactive Bone Substitutes initiates negotiations regarding changes in the organization. Read moreThe company has decided on a new issue of shares without consideration to the company itself. Read more.

Thor Medical is holding a capital markets day today. Read more.

Stille launches imagiQ3 at RSNA 2024. Read more.

DanCann Pharma has decided on directed new issues of DKK 4,5 million and proposed directed new issues of DKK 0,4 million. Read moreThe company calls a meeting. Read more.

CS MEDICA welcomes the Danish government's proposal to make the trial program for prescription-based medical cannabis permanent. Read moreThe company updates on the distribution of CANNORDIC shares. Read more.

Diagonal Bio announces that renowned horse racing jockey and trainer is conducting pilot testing of LAMPlify. Read more.

PolarCool extends contract with French rugby team Racing 92. Read more.

Ray Intelligence: Small savers favor dollar-related investments. Read more.

Prostatype Genomics: The subscription price for the exercise of warrants of series TO 4 has been set at SEK 5,96 per new share. Read more.

Ascelia Pharma decides on the conversion of C shares into common shares for delivery to participants in incentive programs. Read more.

BICO Group has repurchased convertible bonds for a total nominal amount of SEK 118 million. Read more.

Circio announces the allocation of employee stock options to key employees. Read more.